C12N 2760/00034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/00034 (Use of virus or viral component as vaccine) appears on 32 US grants and 47 published applications in this corpus.
Search patents in C12N- Granted patents
- 32
- Published applications
- 47
- Assignees
- 42
- Inventors
- 112
- Latest grant
- 7 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 2 |
| 2015 | 0 | 3 |
| 2016 | 2 | 3 |
| 2017 | 2 | 1 |
| 2018 | 2 | 9 |
| 2019 | 4 | 7 |
| 2020 | 5 | 5 |
| 2021 | 6 | 3 |
| 2022 | 3 | 4 |
| 2023 | 4 | 1 |
| 2024 | 2 | 5 |
| 2025 | 1 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Prefusion PIV F immunogens and their use7 Oct 2025US 12,435,113 B2Institute for Research in Biomedicine
- Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes6 Aug 2024US 12,054,519 B2Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization6 Aug 2024US 12,054,749 B2The Research Foundation for The State University of New York
- Prefusion PIV F immunogens and their use19 Dec 2023US 11,845,778 B2Institute for Research in Biomedicine
- Self-asssembling nanostructure vaccines3 Oct 2023US 11,771,755 B2University of Washington
- Compositions, kits, methods, and methods of administration relating to edwardsiella piscicida vaccine and/or antigen delivery vector systems5 Feb 2026US 2026/0034180 A1
- Prefusion piv f immunogens and their use22 Jan 2026US 2026/0022145 A1Institute for Research in Biomedicine
- Mrna vaccine for bandavirus dabieense and preparation method thereof6 Nov 2025US 2025/0339507 A1Nanjing Medical University
- Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes19 Dec 2024US 2024/0417431 A1Codagenix Inc.
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization19 Dec 2024US 2024/0417699 A1The Research Foundation for The State University of New York
Most cited
By later US patents
- Method for increasing expression of RNA-encoded proteins37US 10,799,602 B2CureVac AG · 2020
- Method for increasing expression of RNA-encoded proteins31US 10,293,060 B2CureVac AG · 2019
- Chromatography based purification strategies for viruses10US 10,894,079 B2Themis Bioscience GmbH · 2021
- Prime-boost regimens involving administration of at least one mRNA construct8US 11,559,570 B2CureVac AG · 2023
- Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization7US 9,957,486 B2The Research Foundation for The State University of New York · 2018